11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Period: 13.06.2026 Expectation: 1000 pips
Go long on USDCAD with 1.38800 target in play
Today at 10:48 AM 15
Period: 20.05.2026 Expectation: 100 pips
Natural gas prices are correcting within upward channel ahead of another rally
Today at 09:39 AM 12
Period: 20.05.2026 Expectation: 1000 pips
Investing in NVIDIA stock with $230 in sight
Today at 09:06 AM 10
Period: 20.01.2028 Expectation: 500 pips
Hot US inflation and geopolitical jitters weigh heavily on EURUSD
Today at 06:26 AM 16
Period: 12.06.2026 Expectation: 4700 pips
Invest in Bitcoin up to $86,000
Yesterday at 10:09 AM 33
Period: 31.05.2026 Expectation: 1900 pips
Buying GBPUSD on low US inflation
Yesterday at 09:54 AM 35
Go to forecasts